Back to top
more

Celgene Corporation (CELG)

(Delayed Data from NSDQ)

$96.88 USD

96.88
5,654,306

+1.67 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $96.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Celgene (CELG) Down 7.9% Since Earnings Report: Can It Rebound?

by Zacks Equity Research

Celgene (CELG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Kinjel Shah headshot

    5 Biotech Stocks to Boost Your Portfolio's Health This Year

    by Kinjel Shah

    Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio.

      Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod

      by Zacks Equity Research

      The biotech sector grabbed headlines last week with drug approvals and licensing deals. Investors will await pipeline development news at the ASCO in the coming week.

        Prothena Restructures Resources, to Cut Workforce by 57%

        by Zacks Equity Research

        Prothena announces a reduction in workforce by 57%, due to the discontinuation of lead program, NEOD001.

          Agios (AGIO) Progressing Well on Pipeline Amid Competition

          by Zacks Equity Research

          Agios (AGIO) has several interesting candidates in its pipeline. However, the company still faces stiff competition.

            bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA

            by Zacks Equity Research

            bluebird (BLUE) obtained Breakthrough Therapy designation from the FDA for Lenti-D for the treatment of patients with cerebral adrenoleukodystrophy, which should expedite its development.

              Prothena (PRTA) Q1 Loss Wider Than Expected, Sales Miss

              by Zacks Equity Research

              Prothena's (PRTA) wider-than-expected loss in the first quarter was disappointing. Sales also missed estimates by a huge margin.

                Celgene (CELG) Q1 Earnings & Sales Beat on Revlimid Strength

                by Zacks Equity Research

                Celgene (CELG) surpasses both earnings and sales estimates in the first quarter on the back of impressive performance from Pomalyst and Otezla.

                  What's in Store for Prothena (PRTA) This Earnings Season?

                  by Zacks Equity Research

                  Prothena (PRTA) has faced quite a few setbacks in the year so far and hence investors will be focused on management's strategy when it reports first-quarter results next week.

                    Ekta Bagri headshot

                    Celgene (CELG) Beats on Q1 Earnings

                    by Ekta Bagri

                    Celgene (CELG) topped both earnings and sales estimates in the first quarter.

                      What Lies Ahead for Ligand (LGND) This Earnings Season? (Revised)

                      by Zacks Equity Research

                      Ligand's (LGND) Captisol formulation technology propels the company to pair up with several leading healthcare companies, which in turn might drive the stock in Q1.

                        What's in the Cards for Aerie (AERI) This Earnings Season?

                        by Zacks Equity Research

                        Investors are expected to focus on Rhopressa's launch and other pipeline updates when it reports results for the first-quarter (scheduled on May 8).

                          Jazz Pharmaceuticals (JAZZ) Q1 Earnings: What's in Store?

                          by Zacks Equity Research

                          Investor focus is likely to be on Xyrem's performance, the lead product of Jazz Pharmaceuticals (JAZZ) for excessive daytime sleepiness. Also, the company's pipeline progress might grab attention.

                            What's in Store for Intrexon (XON) This Earnings Season?

                            by Zacks Equity Research

                            Intrexon Corporation (XON) is expected to report first-quarter 2018 results on May 9, after the market closes, and will provide developmental updates during the quarterly call.

                              What's in Store for Catalyst (CPRX) This Earnings Season?

                              by Zacks Equity Research

                              Catalyst (CPRX) is expected to report first-quarter 2018 results on May 9, after the market closesa and investor's focus will be on pipeline and regulatory updates during the earnings call.

                                Can Celgene (CELG) Keep Its Earnings Streak Alive in Q1?

                                by Zacks Equity Research

                                Celgene (CELG) is likely to maintain momentum in the first quarter on the strength of its lead drug, Revlimid despite recent failures.

                                  Will ACADIA (ACAD) Disappoint Investors This Earnings Season?

                                  by Zacks Equity Research

                                  ACADIA (ACAD) is expected to release first-quarter 2018 results on May 8 and provide updates on its drug, Nuplazid.

                                    Is a Beat in Store for Adverum (ADVM) This Earnings Season?

                                    by Zacks Equity Research

                                    Adverum Biotechnologies (ADVM) is expected to report first-quarter 2018 results, on May 8 and provide updates on its pipeline candidates.

                                      Teva (TEVA) to Report Q1 Earnings: What's in the Cards?

                                      by Zacks Equity Research

                                      Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone is likely to hurt sales of the Specialty segment.

                                        Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings?

                                        by Zacks Equity Research

                                        Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investor focus is expected to remain on the company's pipeline in the first quarter.

                                          What's in Store for ImmunoGen (IMGN) This Earnings Season?

                                          by Zacks Equity Research

                                          ImmunoGen's (IMGN) considerable progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the stock in Q1.

                                            What's in the Cards for Conatus (CNAT) This Earnings Season?

                                            by Zacks Equity Research

                                            Conatus' (CNAT) might see improvement in Q1 courtesy of its lead candidate emricasan. However, the company's portfolio is devoid of an approved product and its resulting revenues.

                                              Is a Beat in the Cards for Gilead (GILD) in Q1 Earnings?

                                              by Zacks Equity Research

                                              Gilead (GILD) is likely to beat earnings estimates when it reports first-quarter results on May 1 driven by strong HIV sales.

                                                What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?

                                                by Zacks Equity Research

                                                During the earnings call, we expect Immune Design to shed light on the progress of its pipeline candidates-CMB305 and G100 .

                                                  What's in the Offing for Keryx (KERX) This Earnings Season?

                                                  by Zacks Equity Research

                                                  Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2018 results on May 3, before the market opens and is expected to provide updates on its lead drug Auryxia.